1. Articles from Sanmartín E , et al.

    1-1 of 1
    1. TIAM1 variants improve clinical outcome in neuroblastoma.

      TIAM1 variants improve clinical outcome in neuroblastoma.

      Oncotarget. 2017 Apr 03;:

      Authors: Sanmartín E, Yáñez Y, Fornés-Ferrer V, Zugaza JL, Cañete A, Castel V, Font de Mora J

      Abstract Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer.

      Read Full Article
      Mentions: Treatment ALK MYCN
    1-1 of 1
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (1 articles) ALK
    2. (1 articles) MYCN
    3. (1 articles) Treatment
  3. Popular Articles

  4. Picture Gallery

    Fighting cancer with immunotherapy: Signaling molecule causes regression of blood vessels Fighting cancer with immunotherapy: Signaling molecule causes regression of blood vessels Latest data show a global increase of 13% in childhood cancer incidence over two decades Success of sensory cell regeneration raises hope for hearing restoration Study finds more childhood cancer survivors would likely benefit from genetic screening Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer Center As radiation therapy declined so did second cancers in childhood cancer survivors